Skip to main content
. Author manuscript; available in PMC: 2018 Jan 18.
Published in final edited form as: Int J Cancer. 2016 Jan 21;139(1):85–98. doi: 10.1002/ijc.29911

Table 2.

Molecular characteristics of HPV DNA+ ESCC tissues

Patient
Number
Patient
Seropositivity
HPV type DNA HPV type
RNAd
p16INK4a

IHC

BSGP5+6+-
PCR/MPGa
TS-E7-
PCR/MPGb
HPV16/18 qPCRc
1 16 E6 16 +
2 6 E6 16 16
3 45 E6 16
4 16 E2 16
5 18 E6 33 invalid
6 16 E6 35
7 16 E1 45
8 18 E6 11
9 16 E1 11
10 16 E1 70 16 invalid

“−“, negative finding; “+“, positive finding; invalid, negative for HPV and β-globin DNA.

a

Available for all currently defined 51 mucosal HPV types (12 HR-, 8 pHR- and 31 LR-HPV); amplicon size: 150 bp HPV, 208 bp β-globin (total 51×118 = 6,018 reactions).

b

Available for 21 mucosal HPV types (12 HR-, 7 pHR- and 2 LR-HPV); amplicon size: ~100 bp HPV (for HPV6, 11, 16, 18, 31, 33, 35, 52, 56 and 66), 117 bp β-globin (total 21×118 = 2,478 reactions). For other HPV types the amplicon size was as previously published by Gheit and colleagues.

c

Available for HPV16 and 18; amplicon size: 104 bp HPV16, 110 bp HPV18, 110 bp β-globin (total 2×118 = 236 reactions).

d

Available for 21 mucosotropic HPV types (12 HR-, 8 pHR- and LR-HPV11); amplicon size: 65–75 bp HPV, 81 bp ubiquitin C. All samples were tested for the presence of HPV16 E6*I mRNA and for the presence of E6*I mRNA of the HPV type defined by genotyping assays and/or serology (total 170 reactions). E.g. for Patient Number 5, the RNA sample was analyzed for the presence of HPV16, HPV18 and HPV33 E6*I mRNA, respectively. No mRNA assay was available for LR-HPV type 6.